Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.

Adoptive cellular immunotherapy, infusions of interleukin 2 (IL-2) in conjunction with in vitro-activated killer cells, has brought new hope to patients with cancer. The broad application of this strategy, however, is constrained by the need for repeated leukapheresis and by the labor-intensive proc...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Proc Natl Acad Sci U S A
Principais autores:	Nakajima, F, Khanna, A, Xu, G, Lagman, M, Haschemeyer, R, Mouradian, J, Wang, J C, Stenzel, K H, Rubin, A L, Suthanthiran, M
Formato:	Artigo
Idioma:	Inglês
Publicado em:	National Academy of Sciences 1994
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC44509/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8058730/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.91.17.7889
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!